Overview
- Omada Health reported that members using its GLP-1 Care Track achieved greater weight loss and better body composition outcomes than those receiving usual care over 12 weeks.
- Among 245 adults with obesity, Omada members lost an average of 6.0% of their starting body weight, compared with 3.3% in the usual-care group.
- The findings, published in Diabetes, Obesity and Metabolism, highlight the potential role of virtual lifestyle support in improving outcomes for people taking GLP-1 medications.
The News
Omada Health announced research showing that its GLP-1 Care Track may improve weight loss and body composition outcomes among people taking GLP-1 medications for obesity. The study followed 245 adults who had started treatment within the previous eight weeks, including 151 participants in Omada’s program and 94 receiving usual care.
After 12 weeks, Omada members lost an average of 6.0% of their starting body weight, compared with 3.3% in the usual-care group. They also achieved a greater reduction in body fat percentage (3.3% versus 1.6%) and a larger increase in muscle mass percentage (0.6% versus 0.2%). Participants reported greater improvements in well-being, physical functioning, and confidence in their ability to lose weight, alongside larger reductions in depression and anxiety symptoms.
The GLP-1 Care Track combines a dedicated health coach, peer support groups, digital meal logging and behavior tracking, AI-powered nutrition support, and personalized exercise plans developed with an exercise specialist. The research was conducted through Omada Insights Lab’s ANSWERS initiative and was published in Diabetes, Obesity and Metabolism. Omada presented the findings at the World Obesity and Weight Management Congress 2026 in Boston.
Industry Perspective
GLP-1 medications can deliver substantial weight loss, but changes in body composition remain an important consideration because some weight lost may come from lean mass. Structured nutrition, exercise, and behavioral support may help patients pursue healthier weight loss while maintaining physical function. However, these findings are based on a 12-week study and do not establish long-term outcomes.
Strategic Impact
The findings support Omada Health’s strategy of extending care beyond physician visits through virtual coaching and personalized lifestyle interventions. By combining GLP-1 treatment support with nutrition, exercise, and behavioral health services, the company is positioning its platform around the quality of weight loss, rather than weight reduction alone. If supported by further research, this approach could strengthen the role of digital health programs in managing obesity alongside pharmacotherapy.
Source: Globenewswire
